Catalyst Pharmaceuticals Inc Stock

Listing Websites about Catalyst Pharmaceuticals Inc Stock

Filter Type:

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, …

(6 days ago) Find the latest Catalyst Pharmaceuticals, Inc. (CPRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CATALYST PHARMACEUTICALS, INC. : CPRX Stock Price

(4 days ago) Company. Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. The Company operates through the development and commercialization of drug products. The Company is developing a pipeline of medicines

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Stock Forecast, Price & News

(6 days ago) Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.14 by $0.02.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (CPRX) Latest Stock News

(2 days ago) Catalyst Pharmaceuticals, Inc. Technical Assessment: Bearish in the Intermediate-Term Volatility in West Texas Intermediate (WTI) crude oil has started to shrink a …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CATALYST PHARMACEUTICALS, INC. : Stock Market News and …

(9 days ago) Catalyst Pharmaceuticals, Inc. fournit des prévisions de revenus pour l'année 2022: 05/10: Catalyst Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le .. 03/17: MISE À JOUR SECTORIELLE: Les actions du secteur des soins de santé se replient alors que .. 03/17

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc (CPRX) Stock Price & News

(8 days ago) Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you make …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX Stock News CATALYST PHARMACEUTICAL …

(3 days ago) Catalyst Pharmaceutical Partners Inc. Stock , CPRX. 7.22-0.31 -4.12% Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX Catalyst Pharmaceuticals Inc — Stock Price and …

(4 days ago) Catalyst Pharmaceuticals Inc NASDAQ Updated May 18, 2022 11:53 PM. CPRX 6.82 0.35 (4.88%). Post-Market 0.06 (0.88%)

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst: A Biopharmaceutical Company Focused on Rare …

(7 days ago) Information for Prescribers and Patients Available. at 1-833-422-8259 and www.yourcatalystpathways.com. Catalyst’s patient services program, Catalyst Pathways, is only open to enrollment for adult LEMS patients, but its staff is available to answer questions from the parents of the small number of LEMS patients who are pediatric patients, and

Url: Visit Now

Category:  Health Detail Drugs


Catalyst Pharmaceuticals Inc. stock outperforms …

(3 days ago) Shares of Catalyst Pharmaceuticals Inc. CPRX, -4.88% slipped 0.76% to $7.79 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, Quote & News

(8 days ago) Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity. Catalyst Pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y. Get the Inside Access Traders Are Using to Profit More and Win 2 months ago - …

Url: Visit Now

Category:  Pharmaceutical,  Health Detail Drugs


Catalyst Pharmaceuticals Inc - Stock Quote CPRX

(Just Now) Learn about Catalyst Pharmaceuticals Inc (CPRX:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. Common Stock (CPRX)

(5 days ago) Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc (CPRX) Stock Gains 3.46% This Week: …

(Just Now) Catalyst Pharmaceuticals Inc stock has gained 30.60% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CPRX stock a score of 69 out of a possible 100.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Stock Forecast: up to 8.858 USD! - CPRX …

(3 days ago) Catalyst Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Catalyst Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Catalyst Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Catalyst Pharmaceuticals's CPRX shares and potentially its …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price Today, Quote

(6 days ago) A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Expected to Post …

(Just Now) 1 day ago · Finally, HC Wainwright lifted their price target on shares of Catalyst Pharmaceuticals from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 7th.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Investors : Catalyst Pharmaceutical

(8 days ago) Investors. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc. stock rises Thursday, outperforms …

(7 days ago) Shares of Catalyst Pharmaceuticals Inc. CPRX, +1.47% advanced 1.47% to $6.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc. stock rises Monday, outperforms …

(5 days ago) Shares of Catalyst Pharmaceuticals Inc. CPRX, +1.30% rallied 1.30% to $7.00 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. Common Stock (CPRX)

(7 days ago) Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX Catalyst Pharmaceuticals Inc. Stock Price & News - WSJ

(3 days ago) View the latest Catalyst Pharmaceuticals Inc. (CPRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average …

(4 days ago) Catalyst Pharmaceuticals stock opened at $6.92 on Friday. The stock has a fifty day moving average price of $7.81 and a two-hundred day moving average price of $7.19. Catalyst Pharmaceuticals has

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by …

(Just Now) ProShare Advisors LLC boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 70.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,216 shares of the biopharmaceutical company’s stock after acquiring an …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals - CPRX - Stock Price & News The …

(9 days ago) Real time Catalyst Pharmaceuticals (CPRX) stock price quote, stock graph, Catalyst Pharmaceuticals Inc (CPRX) Q3 2020 Earnings Call Transcript. Motley Fool Transcribers …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc CPRX - Quotes, Financials, News, …

(5 days ago) Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals Inc Stock Volatility [Standard Deviation]

(3 days ago) Note: Analyzing volatility is one thing. But, you may also benefit by looking at smoothened graphs like average prices over the long term. If so, Catalyst Pharmaceuticals Inc (CPRX) stock chart history report will help you. Below is a table followed by a graph showing 10-year historical volatility measures for Catalyst Pharmaceuticals Inc (CPRX

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX - Catalyst Pharmaceuticals Inc Stock quote - CNNMoney.com

(8 days ago) Find real-time CPRX - Catalyst Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) 6.53. Delayed Data. As of May 09

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX: Catalyst Pharmaceuticals Inc - Stock Price, Quote and News

(2 days ago) Get Catalyst Pharmaceuticals Inc (CPRX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


CPRX - Stock quote for CATALYST PHARMACEUTICALS, INC.

(4 days ago) Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Nasdaq 1/29/2022 Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


This Data Shows Just How Strong Catalyst Pharmaceuticals Inc.

(Just Now) To see how Catalyst Pharmaceuticals Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: CPRX stock’s performance was 0.76% at last check in today’s session, and 35.68% in the past year, while Johnson & Johnson (JNJ) has been trading -0.04% in recent session and positioned 4.15% higher than it was a …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals - CPRX - Stock Price Today - Zacks

(8 days ago) View Catalyst Pharmaceuticals, Inc CPRX investment & stock information. Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News

(6 days ago) Find the latest Catalyst Pharmaceuticals, Inc., CPRX stock market data. Get a full understanding of how Catalyst Pharmaceuticals, Inc. is performing with stock quotes and prices, as well as real

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year …

(8 days ago) Catalyst’s Bumpy Ride: One company that has been a great investment in the last year has been the biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Catalyst Pharmaceuticals

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Is Catalyst Pharmaceuticals a Buy? The Motley Fool

(Just Now) Like many biotech stocks, Catalyst Pharmaceuticals (CPRX 2.43%) has quickly rebounded from the low point it reached during the first quarter's pandemic-driven market plunge. The stock is up about

Url: Visit Now

Category:  Pharmaceutical,  Lung Detail Drugs

Popular Searched

 › Myuhcmedicare.com hwp sign in

 › Optometrist near me that accept medicare

 › Difference between regulated and unregulated drug screen

 › Iin health history form

 › New river medical center va

 › Mayo lake city hospital

 › Webmd pill identifier prescription drugs

 › Myuhcmedicare com hwp products catalog 2022

 › Random drug screen policy template

 › Eastern virginia medical center

Recently Searched

 › Ema drug approval timeline

 › Bit ly extracare health activation program

 › Catalyst pharmaceuticals inc stock

 › Certified medical assistant staffing agencies

 › Aetna medicare prescription drug formulary

 › Staffing agencies for medical assistant

 › Georgia board of medical examiners

 › Drug kits for police

 › Front office medical jobs

 › Cleveland drug bust today

FAQ about Catalyst Pharmaceuticals Inc Stock

Who owns Catalyst Pharmaceuticals stock?

Company insiders that own Catalyst Pharmaceuticals stock include Alicia Grande, Charles B O'keeffe, Gary Ingenito, Patrick J Mcenany, Philip H Coelho and Steve Miller. View institutional ownership trends for Catalyst Pharmaceuticals.

Is Catalyst Pharmaceuticals'stock overvalued or undervalued?

But P/E isn't the only metric one can use gauge how a stock is valued. Catalyst Pharmaceuticals' price-to-book ratio is 5.92, while the biotech sector's average P/B is 3.36, which suggests that the company is overvalued compared with the broader biotech market.

Is Catalyst Pharmaceuticals' (cprx) stock in a bullish cycle?

According to present data Catalyst Pharmaceuticals's CPRX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Currently there seems to be a trend where stocks in the Healthcare Manufacturing sector (s) have been popular in this period.

Can Catalyst Pharmaceuticals'Firdapse drive revenue growth?

Catalyst Pharmaceuticals generated $102.3 million in net product revenues from Firdapse last year, with a total of 532 patients enrolling for treatment. But growth from here will be dependent on whether it can drive wider adoption of its treatments, and on successes in its clinical trials.